Pregestational diabetes

Pathophysiology - Sugar & The Bump

• Maternal hyperglycemia freely crosses the placenta; maternal insulin does not.
• Fetal pancreas responds with islet cell hyperplasia → fetal hyperinsulinemia.
  • Insulin acts as a primary growth hormone → macrosomia (birth weight > 4.0-4.5 kg), organomegaly, and polycythemia.
  • High insulin antagonizes cortisol, inhibiting surfactant production → neonatal respiratory distress syndrome (RDS).

⭐ Fetal hyperinsulinemia is the main driver of macrosomia and can cause profound, persistent neonatal hypoglycemia after birth when the maternal glucose supply is suddenly cut.

Maternal & Fetal Risks - Double Jeopardy Diabetes

• Maternal Risks:

  • Diabetic Ketoacidosis (DKA), often at lower glucose levels (>200 mg/dL).
  • Hypertensive Disorders: Chronic hypertension and a 2-4x ↑ risk of preeclampsia.
  • Progression of End-Organ Damage: Worsening of proliferative retinopathy and nephropathy.
  • Infections: Higher rates of UTIs, chorioamnionitis, and postpartum endometritis.
  • Polyhydramnios.
  • ↑ Cesarean delivery rates due to macrosomia.

• Fetal & Neonatal Risks:

  • Congenital Anomalies (1st trimester hyperglycemia):
    • Most common: Cardiovascular (VSD, TGA).
    • Most specific: CNS defects like neural tube defects and caudal regression syndrome.
  • Macrosomia (>4.5 kg): Leads to shoulder dystocia, birth trauma (e.g., brachial plexus injury).
  • IUGR: Paradoxically can occur with severe, long-standing diabetes with underlying vasculopathy.
  • Neonatal Metabolic Issues:
    • Hypoglycemia (from fetal hyperinsulinemia).
    • Hypocalcemia, polycythemia, hyperbilirubinemia.
  • Respiratory Distress Syndrome (RDS): Fetal hyperinsulinism antagonizes cortisol, delaying surfactant production.

⭐ Caudal regression syndrome, although rare, is a highly specific congenital anomaly associated with pregestational diabetes. An elevated first-trimester HbA1c (>8.5%) is a major predictor.

Management - The Glycemic Gauntlet

• Preconception: Crucial for preventing congenital anomalies.
  • Aim for HbA1c < 6.5%.
  • High-dose folic acid (4 mg/day) to ↓ neural tube defect risk.
• Antepartum:
  • Insulin is the mainstay therapy (doesn't cross placenta). Metformin/glyburide are second-line.
  • Target glucose: Fasting <95, 1-hr postprandial <140, 2-hr postprandial <120 mg/dL.
  • Fetal surveillance (NST, BPP) initiated at 32-34 weeks.
• Intrapartum:
  • IV dextrose and insulin infusion to maintain euglycemia (target 80-110 mg/dL).

⭐ High-Yield: Postpartum insulin requirements plummet dramatically following delivery of the placenta, the primary source of insulin-antagonistic hormones (e.g., hPL). Failure to reduce insulin dosage can lead to severe maternal hypoglycemia.

Intra & Postpartum - The Final Countdown

• Intrapartum Goal: Maintain tight euglycemia (glucose 80-110 mg/dL).
  • Requires IV regular insulin drip & dextrose infusion.
  • Monitor glucose hourly.
• Postpartum Management: Insulin needs ↓ dramatically immediately after delivery.
  • ⚠️ High risk for maternal hypoglycemia.
  • Encourage breastfeeding; it improves glycemic control.
• Neonate Care: Monitor for hypoglycemia, hypocalcemia, polycythemia, and hyperbilirubinemia.

⭐ Postpartum, women often require only 50-60% of their pre-pregnancy insulin dose, especially if breastfeeding.

High‑Yield Points - ⚡ Biggest Takeaways

• Poor 1st-trimester glycemic control is the primary driver of congenital anomalies, especially cardiac and neural tube defects.
• Macrosomia (>4 kg) is a classic fetal complication, significantly increasing the risk of shoulder dystocia.
• Maternal risks include preeclampsia, polyhydramnios, and progression of pre-existing nephropathy or retinopathy.
• Management requires tight glucose control; insulin is the preferred agent.
• Begin fetal surveillance (NST, BPP) at 32-34 weeks.
• Neonates are at high risk for hypoglycemia, hypocalcemia, and hyperbilirubinemia.